NetworkNewsWire
Editorial Coverage: As the legal cannabis
market continues to grow, new deals are creating opportunities for
a range of companies and an influx of investments.
PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF)
(FSE: 18H) (PRVCF
Profile) has teamed up with research
institutions in Australia and gained a government permit to import
cannabis for development of its drug delivery system. Cannabis for
this project will be supplied by Aurora Cannabis (OTCQX:
ACBFF) (TSX: ACB), a company experiencing significant
production growth, including a deal for a new joint venture in
Denmark. ABcann Global (TSX.V: ABCN) (OTCQB:
ABCCF) (ABCCF
Profile) is expanding its production facilities and
utilizing a computer-controlled system to ensure the best growing
conditions, while Aphria, Inc. (TSX: APH) (OTCQB:
APHQF) has developed an expansion strategy using targeted
investment and collaborations to help the company and its partners
grow. And with legal recreational cannabis coming to Canada,
Canopy Growth Corp. (TSX: WEED) (OTC:
TWMJF) has secured a $191 million investment from
Constellation Brands to support new products such as
cannabis-infused soft drinks.
Demand for Cannabis Grows
The cannabis market is growing fast as more states and countries
legalize its use for both medical and recreational purposes. This
is allowing companies to invest heavily in cannabis research to
develop drugs and other products for this growing market. Research
and design is becoming increasingly important.
Research for Preventive Treatment
One of the companies deeply involved in this process is PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB:
PRVCF) (FSE: 18H). The company was founded by
entrepreneurs Stephen Van Deventer and Kimberly Van Deventer. The
pair have been working together since they created business
development and venture capital company Cornerstone Global Partners
in 2009. Since then they have helped create successful cannabis,
hemp and block-chain companies.
Building on a shared interest in the health and wellness market,
they began research into pairing natural remedies with scientific
achievement to provide treatments for health-conscious consumers.
In October 2015 they formed PreveCeutical, combining the words
“preventive” and “pharmaceutical” to express the company’s goal:
medicinally preventing illnesses.
The company’s products are designed to help people stay healthy
rather than dealing with the consequences of illnesses when they
hit. Its therapies, both preventive and curative, use organic and
Nature Identical™ products to ensure that they are in harmony with
natural forces and appealing to environmentally and ethically
conscious consumers. Initial research and product development has
focused on medically acute ailments such as Type 2 diabetes,
obesity, cancer, neurological disorders and pain management.
Focus on Research
PreveCeutical Medical’s corporate office is based in Canada, and
it is making bold advances through research partnerships and a
research team based in Australia. One of its main
partners is UniQuest, the University of Queensland’s
commercialization company. The partnership gives PreveCeutical the
rights to any intellectual property created through work under
their agreement. University of Queensland’s scientific knowledge
and experience in intellectual property management combined with
PreveCeutical’s extensive experience in product development,
corporate strategy and accessing capital markets, creates a
powerful combination of academic and commercial expertise.
Chief Research Officer Dr. Harry Parekh will lead the sol-gel
cannabinoid project from his base at the University of Queensland’s
(UQ) Pharmacy Australia Centre of Excellence (PACE) and is joined
by Chief Science Officer Dr. Makarand Jawadekar, who has 28 years
of experience in R&D with Pfizer, Inc. Dr. Jawadekar was a part
of the team responsible for bringing drugs such as Zolof and Viagra
to the market. They are supported by research collaborators Dr.
Rakesh Veedu and professor Grant Ramm. Dr. Veedu is an emerging
international expert in molecular medicine, while professor Ramm is
currently head of a leading medical research institute in Brisbane,
Australia.
Cannabis Plant Material in Medical Research
PreveCeutical’s work extends to one of the most exciting and
fastest growing areas of medical research — the use of cannabidiols
(CBDs).
PreveCeutical and Aurora Cannabis (OTCQX: ACBFF) (TSX:
ACB) recently announced the grant of three permits by the
Australian Department of Health for the import of CBDs for research
purposes (http://nnw.fm/K2l88). The CBD will go to PACE at the
University of Queensland, where it will be used in a research
program led by Dr. Parekh. This program will be built around
PreveCeutical’s sol-gel nasal drug delivery system. The aim is to
develop sol-gels that deliver CBDs — active, non-psychotropic
ingredients from cannabis — more effectively into the patient’s
system. CBDs can provide valuable solutions for a wide range of
symptoms including pain, inflammation, seizures and neurological
disorders. The research team’s hope is that, through a more direct
nose-to-brain delivery system, they can provide faster, more
effective relief using a time-release, nano bubble technology.
Notably, the cannabis will be provided by Aurora Cannabis. A
licensed producer under the Canadian government’s medical cannabis
regulations, Aurora has over 175,000 square feet of production
facilities. These allow it to provide large volumes of high-grade
medical cannabis for customers such as PreveCeutical.
Better Ways to Deliver Medicine
The sol-gel delivery
system is one of the most exciting developments to come out of
PreveCeutical’s medical research program. It provides medicine in a
liquid form that is squirted up the nose. There, it forms a gel
that slowly and steadily releases the active ingredients over
time.
Sol-gel gets around barriers within the body that limit the
effectiveness of drugs targeting the brain. Traditional delivery
methods, including pills and injections, go through a complex range
of bodily systems before reaching the target. The liver filters out
and metabolizes ingredients, affecting both effectiveness and
delivery time. The blood-brain barrier blocks the path for active
ingredients to reach the brain.
Sol-gel uses hydrogels—molecules that soak up biological fluids
and closely resemble living tissue. Sprayed onto the nasal mucosa,
the medicine has a more direct route to the brain, bypassing bodily
barriers and increasing the effectiveness of the treatment. The
gel’s controlled release of medicine means that delivery is steady
as well as direct, reducing daily doses to once or twice a week
with a 90 percent bioavailability.
Supplying a Growing Research Business
ABcann
Global (TSX.V: ABCN) (OTCQB: ABCCF) is another company
gaining traction in its cannabis business. The company runs a
production facility in Ontario with 14,500 square feet of growing
space. Its computer-controlled environment uses proprietary
lighting systems designed to replicate the natural environment and
provide a perfect space for cannabis to grow. ABcann also owns 65
acres of real estate with proper zoning and existing infrastructure
in place to support the construction of another production facility
of up to 1 million square feet, and is pursuing ongoing global
expansion into the European, Australian and Israeli markets.
Canadian companies are using their experience and favorable
market conditions to expand into other cannabis markets.
Aphria (TSX: APH) (OTCQB: APHQF), a Canadian
medical cannabis company, is working in not only the Canadian but
also the American market. Its strategy of collaboration
and targeted investment has led to significant expansion. This
includes a recent agreement with the Société des alcools du Québec
(SAQ) to supply high-quality cannabis products through retail
outlets in Quebec and an associated e-commerce platform.
Canopy Growth (TSX: WEED) (OTC:
TWMJF) has achieved an even bigger team-up through an
agreement with Constellation Brands. The $42 billion company is
behind the Corona, Modelo and Svedka brands and has taken a $191
million stake in Canopy Growth, providing investment for the
development of cannabis-related soft drinks. Canopy Growth’s other
collaborations include a deal with Sunniva, a vertically integrated
cannabis company focused on the Canadian and Californian markets.
This deal will see a steady supply of cannabis for Canopy Growth,
allowing it to expand its share of the market.
Research is leading the way in the cannabis market, with the
development of new drugs and recreational products. That research
is powering fresh growth on the production side for a sector that’s
healthier than ever before.
For more information on PreveCeutical Medical
Inc., visit PreveCeutical
Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire
services via NetworkWire to
reach all target markets, industries and demographics in the most
effective manner possible, (2) article and editorial syndication to
5,000+ news outlets (3), enhanced press release services to ensure
maximum impact, (4) social media distribution via the Investor
Brand Network (IBN) to nearly 2 million followers, (5) a full array
of corporate communications solutions, and (6) a total news
coverage solution with NNW Prime. As a
multifaceted organization with an extensive team of contributing
journalists and writers, NNW is uniquely positioned to best serve
private and public companies that desire to reach a wide audience
of investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
Source:
NetworkNewsWire
Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
PreveCeutical Medical (QB) (USOTC:PRVCF)
Historical Stock Chart
From Jul 2024 to Aug 2024
PreveCeutical Medical (QB) (USOTC:PRVCF)
Historical Stock Chart
From Aug 2023 to Aug 2024